Insights

How Home Infusion Improves RA Treatment Adherence – and Saves Employers Millions

Image

Rheumatoid arthritis (RA) isn’t just painful—it’s progressive. Missing even a single infusion can lead to joint damage, increased pain and irreversible disability. Yet many RA patients struggle to stay on track with treatment due to:

  • Long travel times and wait times at hospitals or infusion centers
  • Scheduling difficulties—appointments are often booked out weeks or months in advance
  • Financial stress—high out-of-pocket costs from facility fees and markups
  • Work disruptions—taking four hours per infusion on average
  • Fatigue and mobility challenges, making travel especially difficult

The reality? Missed or delayed infusions contribute to 50% of treatment failures.

The result? Increased pain, disease progression, ER visits, and long-term disability claims.

Miss our last post on managing the high cost of RA infusion? Read it here.

 

The High Cost of Non-Adherence for Employers

Skipping or delaying infusions isn’t just a health issue, it’s a major cost driver for employers:

  • RA patients miss 10 additional workdays per year due to treatment delays, flares, or hospitalizations.
  • RA-related absenteeism costs employers over $250 million annually.
  • RA is a leading cause of disability claims—with short-term disability averaging $6,900 per employee, and 19% of claims transitioning to long-term disability.

Every delayed infusion increases the risk of: 

  • Emergency room visits
  • Expensive hospital stays
  • Long-term joint damage, forcing early workforce exits

Home Infusion: The Adherence Game-Changer

Leap eliminates the biggest barriers to adherence by bringing treatment directly to patients, helping them stay on schedule and stay healthy.

Here’s how home infusion directly improves adherence for RA patients:

  • Eliminates travel time: infusions happen at home, on the patient’s schedule
  • Reduces missed workdays: patients save hours per treatment
  • Lowers costs: transparent pricing removes unnecessary markups and surprise bills
  • Improves patient satisfaction: 98% of Leap Health patients report high satisfaction

With better adherence, RA patients experience fewer flares, fewer hospitalizations, and better long-term outcomes.

The Financial Impact: Savings for Employers

  • RA patients have an average healthcare expenditure of up to $24,069 annually 
  • Leap Health saves employers an average of $24,000 per RA patient per year
  • Reducing disability claims alone could save companies millions annually

It’s simple: Better adherence = lower costs, healthier employees, and a stronger workforce.

Time to Rethink RA Infusion Care

The traditional hospital-based model is failing RA patients, and driving up costs for employers. Home infusion solves both problems.

Learn how Leap is transforming RA treatment adherence and saving employers millions today.

Share this post

More insights

Image
Education

The Infusion Cost Crisis: Why Medical Benefit Drug Spend Keeps Escalating

For employers, however, infusion care has quietly become one of the fastest-growing and least unders...

Read article
Image
News

Leap Joins the Castlight Ecosystem to Simplify Infusion Care

Leap has joined the Castlight ecosystem to give TPAs and employers a more transparent, predictable, ...

Read article
Image
Insights

Rebates, what rebates? Understanding pharmacy rebates for J-Code drugs

Pharmacy rebates are manufacturer-paid discounts, typically negotiated behind

Read article
Image
Education

Demystifying Specialty Drug Pricing Acronyms, and Why They All Fail Employers

Behind the exorbitant costs of infusion therapies, you’ll find layers of complexity—and three acrony...

Read article
Image
Clinical

Safely Infusing Immunoglobulin in the Home Setting: Clinical Considerations and Best Practices

Immunoglobulin (Ig) therapies are essential in the treatment of primary immunodeficiency (PID), chro...

Read article
Image
News

Leap and Amwins Partner to Deliver Low-Cost, Convenient Infusion Therapy

Leap and Amwins Rx, today announced a strategic collaboration that will bring significant benefits t...

Read article
Image
Case Study

Bringing Relief Home for Annie

Helping a working parent stay on track with infusion care

Read article
Image
Insights

How Leap Reduces the Total Cost of Multiple Sclerosis Care

For patients requiring long-term MS infusions like Ocrevus or Tysabri, traditional hospital-based tr...

Read article
Image
News

Leap and Blackhawk Claims Service Partner to Reduce Specialty Medication Costs and Improve Patient Access

We're so excited to announce our strategic partnership with Blackhawk Claims Service, a leading thir...

Read article
Image
Insights

The High Cost of RA Infusions – and How Leap Fixes It

For many patients, biologic infusions such as Remicade, Actemra, and Orencia are essential but they ...

Read article